As of Q4'25 (2025-12-31), CVS reported an EPS Diluted of 2.3 USD, marking a significant rebound from the previous quarter’s negative EPS of -3.13 USD in Q3'25. The year-over-year EPS growth for Q4'25 reached 75.57%, indicating a strong recovery in earnings performance at the end of the period. From Q1'23 to Q4'25, CVS’s EPS Diluted exhibited considerable volatility, with notable declines in Q1'24 (0.88 USD) and a sharp drop to -3.13 USD in Q3'25, followed by a rapid recovery to 2.3 USD in Q4'25. The EPS Growth (YoY) trend mirrors this volatility, with significant negative growth in Q3'24 (-96%) and Q3'25 (-4571.43%), but strong positive growth in Q3'23 (167.31%) and Q4'25 (75.57%). Overall, the chart highlights periods of both sharp decline and robust recovery, reflecting an unstable earnings environment over the observed quarters.